Activating somatic mutations of FGFR2 have been reported in some cancers including lung squamous cell carcinoma, gastric cancer, cervical carcinoma, and endometrial carcinoma, implicating its role in cancer development [60]–[62]. This evidence concerns the gene FGFR2 and squamous cell lung carcinoma.